A First-in-human Study to Assess OT-C001 (Amplified/Activated Allogenic Natural Killer Cells) in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

Inclusion Criteria:

* ≥18 years of age
* histologically confirmed diagnosis of R/R DLBCL-NOS without further standard treatment options including those relapsing after or ineligible for CAR T-cell therapy
* with evaluable disease
* with adequate biological parameters at baseline
* ECOG performance status ≤1
* life expectancy \>3 months as assessed by the investigator

Exclusion Criteria:

* Receive concomitantly any antitumor-directed drug therapy
* Any vaccination with live virus vaccines before or during treatment
* With severe atopic predisposition who need a treatment with monoclonal antibodies, allergen immunotherapy, or long-term systemic corticosteroids
* Major surgery within 3 weeks
* With rapidly progressing disease that includes massive uncontrolled pleural, pericardial, or peritoneal effusions, pulmonary lymphangitis, and over 50% liver involvement
* Ongoing immune-related tocivities or adverse events grade \>1 not resolved from previous therapies except vitiligo, stable neuropathy up to grade 2, hair loss, and stable endocrinopathies with substitutive hormone therapy
* Documented history of active autoimmune disorders requiring systemic immunosuppressive therapy within the last 12 months
* Primary or secondary immune deficiency
* Active and uncontrolled infections requiring intravenous antibiotic or antiviral treatment
* Seropositive (except after vaccination or confirmed cure for hepatitis) for HIV, HBV, or HCV
* Clinically significant cardiac disease including heart failure, uncontrolled hypertension, pre-existing arrhythmia, uncontrolled angina pectoris, or myocardial infarction within 12 months
* Dementia or altered mental status that would prohibit informed consent
* Other malignancy within the last 3 years except adequately treated nonmelanoma skin cancer, in situ carcinoma of the uterine cervix, or myelodysplastic syndromes